Research progress of the target proteins by proteasome activator REG<inline-formula><tex-math id="M2">\begin{document}$\gamma $\end{document}</tex-math></inline-formula> in human cancers

CHEN Shao-jun; LI Xiao-tao; ZHENG Jun-hua

doi:10.3969/j.issn.1000-5641.2018.02.013

Issue 2

Mar. 2018

Turn off MathJax

Article Contents

Article Navigation > Journal of East China Normal University (Natural Sciences) > 2018 > (2): 125-130, 159

CHEN Shao-jun, LI Xiao-tao, ZHENG Jun-hua. Research progress of the target proteins by proteasome activator REG$\gamma $ in human cancers[J]. Journal of East China Normal University (Natural Sciences), 2018, (2): 125-130, 159. doi: 10.3969/j.issn.1000-5641.2018.02.013

Citation:

CHEN Shao-jun, LI Xiao-tao, ZHENG Jun-hua. Research progress of the target proteins by proteasome activator REG$\gamma $ in human cancers[J]. Journal of East China Normal University (Natural Sciences), 2018, (2): 125-130, 159. doi: 10.3969/j.issn.1000-5641.2018.02.013

Citation:

PDF( 615 KB)

Research progress of the target proteins by proteasome activator REG$\gamma $ in human cancers

doi: 10.3969/j.issn.1000-5641.2018.02.013

1.
Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, China
2.
Institute of Biomedical Sciences, East China Normal University, Shanghai 200241, China

Received Date: 2017-02-20
Publish Date: 2018-03-25

Abstract

Abstract

The proteasome activator REG$\gamma $, which is a member of REG (11 S) proteasome activator family, can stimulate the proteolytic activity of the 20 S core proteasome to degrade proteins independent of ubiquitination and ATP. In recent years, more and more studies show that REG$\gamma $ is dysregulated in various human cancers and closely related to the oncogenesis and development of cancers. The potential mechanism by which REG$\gamma $ exerts its role in cancer development is degradation of various target proteins. We now review the target proteins of REG$\gamma $ in human cancers in order to further understand the mechanism by which REG$\gamma $ exerts its role in cancer development, and to uncover the potential of REG$\gamma $ to serve as a new marker for diagnosis and a novel target for treatment in human cancers.
- \begin{document}$\gamma $\end{document}')">REG\begin{document}$\gamma $\end{document},
- cancer,
- target proteins

FullText(HTML)

References(50)

References

[1]	NIKAIDO T, SHIMADA K, SHIBATA M, et al. Cloning and nucleotide sequence of cDNA for Ki antigen, a highly conserved nuclear protein detected with sera from patients with systemic lupus erythematosus[J]. Clinical and Experimental Immunology, 1990, 79(2):209-214. doi: 10.1111/j.1365-2249.1990.tb05180.x
[2]	RECHSTEINER M, REALINI C, USTRELL V. The proteasome activator 11S REG (PA28) and class Ⅰantigen presentation[J]. The Biochemical Journal, 2000, 345(1):1-15. http://www.ncbi.nlm.nih.gov/pubmed/10600633
[3]	MAO I, LIU J, LI X, et al. REGgamma, a proteasome activator and beyond?[J]. Cellular and Molecular Life Sciences:CMLS, 2008, 65(24):3971-3980. doi: 10.1007/s00018-008-8291-z
[4]	LI X, LONARD D M, JUNG S Y, et al. The SRC-3/AIB1 coactivator is degraded in a ubiquitin-and ATPindependent manner by the REGgamma proteasome[J]. Cell, 2006, 124(2):381-392. doi: 10.1016/j.cell.2005.11.037
[5]	GOLDBERG A L. Protein degradation and protection against misfolded or damaged proteins[J]. Nature, 2003, 426(6968):895-899. doi: 10.1038/nature02263
[6]	JUNG T, CATALGOL B, GRUNE T. The proteasomal system[J]. Molecular Aspects of Medicine, 2009, 30(4):191-196. doi: 10.1016/j.mam.2009.04.001
[7]	GERMAIN D. Ubiquitin-dependent and -independent mitochondrial protein quality controls:Implications in ageing and neurodegenerative diseases[J]. Molecular Microbiology, 2008, 70(6):1334-1341. doi: 10.1111/mmi.2008.70.issue-6
[8]	VOGES D, ZWICKL P, BAUMEISTER W. The 26S proteasome:A molecular machine designed for controlled proteolysis[J]. Annual Review of Biochemistry, 1999, 68:1015-1068. doi: 10.1146/annurev.biochem.68.1.1015
[9]	WILK S, CHEN W E, MAGNUSSON R P. Properties of the nuclear proteasome activator PA28gamma (REGgamma)[J]. Archives of Biochemistry and Biophysics, 2000, 383(2):265-271. doi: 10.1006/abbi.2000.2086
[10]	MURATA S, KAWAHARA H, TOHMA S, et al. Growth retardation in mice lacking the proteasome activator PA28gamma[J]. The Journal of Biological Chemistry, 1999, 274(53):38211-38215. doi: 10.1074/jbc.274.53.38211
[11]	BARTON L F, RUNNELS H A, SCHELL T D, et al. Immune defects in 28-kDa proteasome activator gammadeficient mice[J]. Journal of Immunology, 2004, 172(6):3948-3954. doi: 10.4049/jimmunol.172.6.3948
[12]	YU G, ZHAO Y, HE J, et al. Comparative analysis of REGgamma expression in mouse and human tissues[J]. Journal of Molecular Cell Biology, 2010, 2(4):192-198. doi: 10.1093/jmcb/mjq009
[13]	HE J, CUI L, ZENG Y, et al. REGgamma is associated with multiple oncogenic pathways in human cancers[J]. BMC Cancer, 2012(12):75. http://www.ncbi.nlm.nih.gov/pubmed/22361172
[14]	WANG X, TU S, TAN J, et al. REGgamma:A potential marker in breast cancer and effect on cell cycle and proliferation of breast cancer cell[J]. Medical Oncology, 2011, 28(1):31-41. doi: 10.1007/s12032-010-9546-8
[15]	CHAI F, LIANG Y, BI J, et al. High expression of REGgamma is associated with metastasis and poor prognosis of patients with breast cancer[J]. International Journal of Clinical and Experimental Pathology, 2014, 7(11):7834-7843. http://www.ncbi.nlm.nih.gov/pubmed/25550823
[16]	TIAN M, XIAOYI W, XIAOTAO L, et al. Proteasomes reactivator REGgamma enchances oncogenicity of MDAMB-231 cell line via promoting cell proliferation and inhibiting apoptosis[J]. Cellular and Molecular Biology, 2009, 55(Suppl):OL1121-1131. http://www.ncbi.nlm.nih.gov/pubmed/19656465
[17]	ZHANG M, GAN L, REN G S. REGgamma is a strong candidate for the regulation of cell cycle, proliferation and the invasion by poorly differentiated thyroid carcinoma cells[J]. Brazilian Journal of Medical and Biological Research, 2012, 45(5):459-465. doi: 10.1590/S0100-879X2012007500035
[18]	GUO J, HAO J, JIANG H, et al. Proteasome activator subunit 3 promotes pancreatic cancer growth via c-Mycglycolysis signaling axis[J]. Cancer Letters, 2017, 386:161-167. doi: 10.1016/j.canlet.2016.08.018
[19]	KONDO M, MORⅡSHI K, WADA H, et al. Upregulation of nuclear PA28gamma expression in cirrhosis and hepatocellular carcinoma[J]. Experimental and Therapeutic Medicine, 2012, 3(3):379-385. doi: 10.3892/etm.2011.415
[20]	LI L P, CHENG W B, LI H, et al. Expression of proteasome activator REGgamma in human laryngeal carcinoma and associations with tumor suppressor proteins[J]. Asian Pacific Journal of Cancer Prevention:APJCP, 2012, 13(6):2699-2703. doi: 10.7314/APJCP.2012.13.6.2699
[21]	LI J, FENG X, SUN C, et al. Associations between proteasomal activator PA28gamma and outcome of oral squamous cell carcinoma:Evidence from cohort studies and functional analyses[J]. EBioMedicine, 2015, 2(8):851-858. doi: 10.1016/j.ebiom.2015.07.004
[22]	LIAO L, KUANG S Q, YUAN Y, et al. Molecular structure and biological function of the cancer-amplified nuclear receptor coactivator SRC-3/AIB1[J]. The Journal of Steroid Biochemistry and Molecular Biology, 2002, 83(1-5):3-14. doi: 10.1016/S0960-0760(02)00254-6
[23]	YAN J, TSAI S Y, TSAI M J. SRC-3/AIB1:Transcriptional coactivator in oncogenesis[J]. Acta Pharmacologica Sinica, 2006, 27(4):387-394. doi: 10.1111/aphs.2006.27.issue-4
[24]	HUANG H, WENG H, ZHOU H, et al. Attacking c-Myc:Targeted and combined therapies for cancer[J]. Current Pharmaceutical Design, 2014, 20(42):6543-6554. doi: 10.2174/1381612820666140826153203
[25]	LI S, JIANG C, PAN J, et al. Regulation of c-Myc protein stability by proteasome activator REGgamma[J]. Cell Death and Differentiation, 2015, 22(6):1000-1011. doi: 10.1038/cdd.2014.188
[26]	ZHAN T, RINDTORFF N, BOUTROS M. Wnt signaling in cancer[J]. Oncogene, 2017, 36(11):1461-1473. doi: 10.1038/onc.2016.304
[27]	STEWART D J. Wnt signaling pathway in non-small cell lung cancer[J]. Journal of The National Cancer Institute, 2014, 106(1):djt356. doi: 10.1093/jnci/djt356
[28]	SAWA M, MASUDA M, YAMADA T. Targeting the Wnt signaling pathway in colorectal cancer[J]. Expert Opinion on Therapeutic Targets, 2016, 20(4):419-429. doi: 10.1517/14728222.2016.1098619
[29]	XU Q, KRAUSE M, SAMOYLENKO A, et al. Wnt signaling in renal cell carcinoma[J]. Cancers, 2016, 8(6):57. doi: 10.3390/cancers8060057
[30]	LUO J. Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy[J]. Cancer Letters, 2009, 273(2):194-200. doi: 10.1016/j.canlet.2008.05.045
[31]	LI L, DANG Y, ZHANG J, et al. REGgamma is critical for skin carcinogenesis by modulating the Wnt/betacatenin pathway[J]. Nature Communications, 2015(6):6875. https://www.nature.com/articles/ncomms7875/metrics
[32]	STRACQUADANIO G, WANG X, WALLACE M D, et al. The importance of p53 pathway genetics in inherited and somatic cancer genomes[J]. Nature Reviews Cancer, 2016, 16(4):251-265. doi: 10.1038/nrc.2016.15
[33]	ZHANG Z, ZHANG R. Proteasome activator PA28 gamma regulates p53 by enhancing its MDM2-mediated degradation[J]. The EMBO Journal, 2008, 27(6):852-864. doi: 10.1038/emboj.2008.25
[34]	LIU J, YU G, ZHAO Y, et al. REGgamma modulates p53 activity by regulating its cellular localization[J]. Journal of Cell Science, 2010, 123(23):4076-4084. doi: 10.1242/jcs.067405
[35]	WEINBERG W C, DENNING M F. P21Waf1 control of epithelial cell cycle and cell fate[J]. Critical Reviews in Oral Biology and Medicine:An Official Publication of the American Association of Oral Biologists, 2002, 13(6):453-464. doi: 10.1177/154411130201300603
[36]	LI X, AMAZIT L, LONG W, et al. Ubiquitin-and ATP-independent proteolytic turnover of p21 by the REGgamma-proteasome pathway[J]. Molecular Cell, 2007, 26(6):831-842. doi: 10.1016/j.molcel.2007.05.028
[37]	KOBAYASHI T, WANG J, AL-AHMADIE H, et al. ARF regulates the stability of p16 protein via REGgammadependent proteasome degradation[J]. Molecular Cancer Research:MCR, 2013, 11(8):828-833. doi: 10.1158/1541-7786.MCR-13-0207
[38]	CHEN X, BARTON L F, CHI Y, et al. Ubiquitin-independent degradation of cell-cycle inhibitors by the REGgamma proteasome[J]. Molecular Cell, 2007, 26(6):843-852. doi: 10.1016/j.molcel.2007.05.022
[39]	ZHU H, KAVSAK P, ABDOLLAH S, et al. A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation[J]. Nature, 1999, 400(6745):687-693. doi: 10.1038/23293
[40]	KWON A, LEE H L, WOO K M, et al. SMURF1 plays a role in EGF-induced breast cancer cell migration and invasion[J]. Molecules and Cells, 2013, 36(6):548-555. doi: 10.1007/s10059-013-0233-4
[41]	KWEI K A, SHAIN A H, BAIR R, et al. SMURF1 amplification promotes invasiveness in pancreatic cancer[J]. PloS One, 2011, 6(8):e23924. doi: 10.1371/journal.pone.0023924
[42]	WANG W, REN F, WU Q, et al. MicroRNA-497 inhibition of ovarian cancer cell migration and invasion through targeting of SMAD specific E3 ubiquitin protein ligase 1[J]. Biochemical and Biophysical Research Communications, 2014, 449(4):432-437. doi: 10.1016/j.bbrc.2014.05.053
[43]	LIU S, LAI L, ZUO Q, et al. PKA turnover by the REGgamma-proteasome modulates FoxO1 cellular activity and VEGF-induced angiogenesis[J]. Journal of Molecular and Cellular Cardiology, 2014, 72:28-38. doi: 10.1016/j.yjmcc.2014.02.007
[44]	LI L, ZHAO D, WEI H, et al. REGgamma deficiency promotes premature aging via the casein kinase 1 pathway[J]. Proceedings of The National Academy of Sciences of The United States of America, 2013, 110(27):11005-11010. doi: 10.1073/pnas.1308497110
[45]	SCHITTEK B, SINNBERG T. Biological functions of casein kinase 1 isoforms and putative roles in tumorigenesis[J]. Molecular Cancer, 2014, 13:231. doi: 10.1186/1476-4598-13-231
[46]	DONG S, JIA C, ZHANG S, et al. The REGgamma proteasome regulates hepatic lipid metabolism through inhibition of autophagy[J]. Cell Metabolism, 2013, 18(3):380-391. doi: 10.1016/j.cmet.2013.08.012
[47]	LIN L, BAEHRECKE E H. Autophagy, cell death, and cancer[J]. Molecular & Cellular Oncology, 2015, 2(3):e985913. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905302/
[48]	XU J, ZHOU L, JI L, et al. The REGgamma-proteasome forms a regulatory circuit with IkappaBvarepsilon and NFkappaB in experimental colitis[J]. Nature Communications, 2016(7):10761. http://www.ncbi.nlm.nih.gov/pubmed/26899380
[49]	KANAI K, ARAMATA S, KATAKAMI S, et al. Proteasome activator PA28 gamma stimulates degradation of GSK3-phosphorylated insulin transcription activator MAFA[J]. Journal of Molecular Endocrinology, 2011, 47(1):119-127. doi: 10.1530/JME-11-0044
[50]	MORⅡSHI K, OKABAYASHI T, NAKAI K, et al. Proteasome activator PA28gamma-dependent nuclear retention and degradation of hepatitis C virus core protein[J]. Journal of Virology, 2003, 77(19):10237-10249. doi: 10.1128/JVI.77.19.10237-10249.2003